Episode Details

Back to Episodes
FDA APPROVES MERCK’S RSV SHOT DESPITE ALARMING INFANT TRIAL DATA

FDA APPROVES MERCK’S RSV SHOT DESPITE ALARMING INFANT TRIAL DATA

Published 1 year, 1 month ago
Description
Del and Jefferey dive into the troubling numbers behind Merck’s new RSV shot for infants, recently greenlit by the FDA. Trial data revealed higher rates of deaths and severe respiratory illness in vaccinated babies, yet the FDA overlooked this concerning trial data.

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us